Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
KYMR submitted a Form 144 reporting a proposed sale of 3,000 common shares tied to an exercise of stock options on 05/11/2026, with settlement indicated as cash and Morgan Stanley Smith Barney LLC listed in the securities table.
The filing also lists prior 10b5-1 sales by Elena Ridloff: 4,600 shares on 04/01/2026 for $392,921.88 and 7,400 shares on 03/31/2026 for $631,738.74.
Kymera Therapeutics ownership update: institutional investor FMR LLC reports beneficial ownership of 11,681,450.45 shares of Common Stock, representing 14.3% of the class. The filing lists sole voting power of 11,666,707 and sole dispositive power of 11,681,450.45, with an exhibit referencing a 13d-1(k) agreement.
Kymera Therapeutics reported higher collaboration revenue and a wider loss for the quarter ended March 31, 2026. Collaboration revenue rose to $34.4 million, driven by recognition of deferred revenue from its Gilead CDK2 partnership, while the company recorded a net loss of $69.2 million and basic and diluted net loss per share of $0.71.
Total operating expenses increased to $118.5 million, led by research and development spending of $98.2 million as multiple programs advance. Kymera ended the quarter with $1.55 billion in cash, cash equivalents and marketable securities and $1.54 billion of stockholders’ equity, providing substantial funding for its clinical-stage targeted protein degradation pipeline.
The company’s Sanofi IRAK4 collaboration did not contribute revenue this quarter after prior milestones, while Gilead collaboration revenue fully relieved related deferred revenue. After quarter-end, Gilead exercised its option to exclusively license KT-200, triggering a $45 million milestone expected to be recognized as second-quarter 2026 revenue.
Kymera Therapeutics reported first quarter 2026 results, highlighting pipeline progress and stronger collaboration revenue. Collaboration revenue was $34.4 million, up from $22.1 million a year earlier, driven by its partnership with Gilead Sciences.
Research and development expenses rose to $98.2 million and general and administrative expenses to $20.4 million, leading to a net loss of $69.2 million, compared with $65.6 million in the prior-year quarter. Kymera ended March 31, 2026 with $1.55 billion in cash, cash equivalents and investments and expects this balance to fund operations into 2029 while advancing KT-621, KT-579 and partnered programs including KT-200 and KT-485/SAR447971.
Kymera Therapeutics, Inc. director and CEO Nello Mainolfi reported an exercise-and-sell transaction in Kymera common stock. On April 29, 2026, he exercised stock options to acquire 30,000 shares at $2.08 per share and then sold 30,000 shares of common stock in open-market trades.
The sales were split into blocks of 936, 12,059, and 17,005 shares at weighted average prices of about $82.45, $81.70, and $80.74. According to the filing, these trades were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, Mainolfi directly held 666,195 shares of Kymera common stock.
Kymera Therapeutics is asking shareholders to vote at its virtual 2026 annual meeting on June 24, 2026. Holders of 82,257,588 common shares as of April 27, 2026 may participate online.
Shareholders will elect four Class III directors to serve until 2029, cast a non-binding advisory “Say‑on‑Pay” vote on executive compensation, and vote on ratifying Ernst & Young LLP as independent auditor for 2026. The board recommends voting “FOR” all three proposals.
The proxy outlines a staggered board structure, committee independence, and a clawback policy, and describes Kymera’s performance-based pay philosophy, including a 125% corporate bonus funding factor for 2025 tied to pipeline progress, strategic partnerships, and a year‑end cash balance of about $1.6 billion.
Kymera Therapeutics director Bruce Booth reported option exercises and related share sales in Kymera Therapeutics, Inc. common stock. On April 22, 2026 he exercised options for 259 shares at $20.00 per share and 5,641 shares at $14.18 per share, then sold 5,900 shares in open‑market transactions at a weighted average price of about $89.96 per share, leaving no directly owned shares.
Entities associated with Atlas Venture made additional small sales of 12 and 88 shares at $90.08 per share. After these trades, Atlas Venture Fund X, L.P. held 674,944 shares and Atlas Venture Opportunity Fund I, L.P. held 3,899,829 shares, with Booth disclaiming Section 16 beneficial ownership except to any pecuniary interest. The filing notes these sales were made under pre‑arranged Rule 10b5‑1 trading plans adopted in December 2025.
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported a mix of option exercises and a small stock sale. On April 22, 2026, he exercised stock options for a total of 300 shares of common stock at exercise prices of $43.50 and $30.17 per share, then made an open-market sale of 300 shares at $90.00 per share. After these transactions, he directly held 61,202 shares of Kymera common stock. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, indicating they were scheduled in advance rather than timed discretionarily.
KYMR notice: Section 144 filings report proposed sales of Common Stock by several holders. Examples include Atlas Venture Fund X, L.P. proposing 71,814 shares on 03/02/2026 for $6,472,674.74 and other smaller dispositions in March–April 2026.